Tsung-Cheng Chang

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Breast Cancer Cells

Endoplasmic Reticulum

Estrogen Receptor

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)